person · Reporting owner

Ballinger Kevin J.

Disclosed activity across 4 companies

Tapewire entity: 41681
SEC CIK: 0001566080

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BOSTON SCIENTIFIC CORPBSX · Entity 1897	EVP & Pres, Interven Cardio	March 03, 2020	March 05, 2020
CVRx, Inc.CVRX · Entity 6920	Director	June 01, 2026	June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BOSTON SCIENTIFIC CORP

Report date March 03, 2020 · Filed March 05, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	80,085	Last balance in matching sequence After 2020-03-04 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-03-03 · Exercise / conversion · Acquired 3,303 · Balance 83,388 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Row 2 · 2020-03-03 · Tax withholding · Disposed 1,507 · Balance 81,881 F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Row 3 · 2020-03-04 · Sale · Disposed 1,796 · Balance 80,085 F3: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-03-03	Direct	6,606	Reported balance After 2020-03-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-03-03 · Exercise / conversion · Disposed 3,303 · Balance 6,606 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

F3: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.

CVRx, Inc.

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,720	Reported balance After 2026-06-01 transaction · row 1 1 source row Row 1 · 2026-06-01 · Grant · Acquired 8,720 · Balance 8,720 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01	Direct	11,182	Reported balance After 2026-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-01 · Grant · Acquired 11,182 · Balance 11,182 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Shockwave Medical, Inc.

Report date May 31, 2024 · Filed May 31, 2024

Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-05-31 transaction · row 1 1 source row Row 1 · 2024-05-31 · Disposition to issuer · Disposed 1,733 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),

F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.

Silk Road Medical Inc

Report date September 17, 2024 · Filed September 18, 2024

Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-09-17 transaction · row 1 1 source row Row 1 · 2024-09-17 · Disposition to issuer · Disposed 23,666 · Balance 0 F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.

F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.

F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 24, 2018 Filed Feb 26, 2018 22:41 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	2,867	$0.00	$0.00	Disclosure SEC source: 0001225208-18-004198 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 23, 2018 Filed Feb 26, 2018 22:41 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionDeferred Stock Units · Derivative	3,679	$0.00	$0.00	Disclosure SEC source: 0001225208-18-004198 · doc4.xml · derivative · entry 5 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,358 Underlying: Common Stock · 3,679 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document
February 23, 2018 Filed Feb 26, 2018 22:41 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	1,678	$27.20	$45,641.60	Disclosure SEC source: 0001225208-18-004198 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,096 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 23, 2018 Filed Feb 26, 2018 22:41 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	3,679	$0.00	$0.00	Disclosure SEC source: 0001225208-18-004198 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 22, 2018 Filed Feb 23, 2018 21:10 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionDeferred Stock Units · Derivative	3,766	$0.00	$0.00	Disclosure SEC source: 0001225208-18-003998 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,298 Underlying: Common Stock · 3,766 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document
February 22, 2018 Filed Feb 23, 2018 21:10 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	1,718	$26.48	$45,492.64	Disclosure SEC source: 0001225208-18-003998 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,095 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 22, 2018 Filed Feb 23, 2018 21:10 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	3,766	$0.00	$0.00	Disclosure SEC source: 0001225208-18-003998 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 15, 2018 Filed Feb 20, 2018 21:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantStock Option (Right to Buy) · Derivative	48,665	$0.00 Strike: $27.09	$0.00	Disclosure SEC source: 0001225208-18-003381 · doc4.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,665 Underlying: Common Stock · 48,665 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document
February 15, 2018 Filed Feb 20, 2018 21:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantDeferred Stock Units · Derivative	16,149	$0.00	$0.00	Disclosure SEC source: 0001225208-18-003381 · doc4.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,149 Underlying: Common Stock · 16,149 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document
February 12, 2018 Filed Feb 14, 2018 21:25 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantPerformance Share Units · Derivative	16,117	$0.00	$0.00	Disclosure SEC source: 0001225208-18-002886 · doc4.xml · derivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,117 Underlying: Common Stock · 16,117 shares Expires 2019-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F4 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F4 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F4 · balance_after: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. Read SEC document
February 12, 2018 Filed Feb 14, 2018 21:25 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	13,890	$26.18	$363,640.20	Disclosure SEC source: 0001225208-18-002886 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,047 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 12, 2018 Filed Feb 14, 2018 21:25 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantCommon Stock	36,786	$0.00	$0.00	Disclosure SEC source: 0001225208-18-002886 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,937 F2 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2017 and was subject to the completion of the concurrent three-year individual service period. On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 05, 2018 Filed Feb 14, 2018 21:25 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GiftCommon Stock	375	$0.00	$0.00	Disclosure SEC source: 0001225208-18-002886 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,151 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
January 01, 2018 Filed Jan 3, 2018 21:49 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionPerformance Share Units · Derivative	20,012	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000355 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,012 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.exercise_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.expiration_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document
January 01, 2018 Filed Jan 3, 2018 21:49 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	6,973	$24.79	$172,860.67	Disclosure SEC source: 0001225208-18-000355 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,448 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
January 01, 2018 Filed Jan 3, 2018 21:49 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	20,012	$0.00	$0.00	Disclosure SEC source: 0001225208-18-000355 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
May 17, 2017 Filed May 18, 2017 20:25 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	SaleCommon Stock	16,088	$26.18	$421,116.27	Disclosure SEC source: 0001225208-17-010054 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,366 F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.17 to $26.181, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
May 17, 2017 Filed May 18, 2017 20:25 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	SaleCommon Stock	12,776	$26.09	$333,337.34	Disclosure SEC source: 0001225208-17-010054 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,454 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $26.09 and $26.10. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
May 03, 2017 Filed May 18, 2017 20:25 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GiftCommon Stock	400	$0.00	$0.00	Disclosure SEC source: 0001225208-17-010054 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,230 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
March 03, 2017 Filed Mar 6, 2017 23:07 UTC Amendment	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantStock Option (Right to Buy) · Derivative	52,816	$0.00 Strike: $24.98	$0.00	Disclosure SEC source: 0001225208-17-005662 · doc4a.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,816 Underlying: Common Stock · 52,816 shares Expires 2027-03-03 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document
March 03, 2017 Filed Mar 6, 2017 23:07 UTC Amendment	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantPerformance Share Units · Derivative	16,513	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005662 · doc4a.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,513 Underlying: Common Stock · 16,513 shares Expires 2018-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F4 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F4 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F4 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document
March 03, 2017 Filed Mar 6, 2017 23:07 UTC Amendment	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantDeferred Stock Units · Derivative	16,513	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005662 · doc4a.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,513 Underlying: Common Stock · 16,513 shares Expires 2022-03-03 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document
February 28, 2017 Filed Mar 2, 2017 01:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantStock Option (Right to Buy) · Derivative	57,641	$0.00 Strike: $24.55	$0.00	Disclosure SEC source: 0001225208-17-005150 · doc4.xml · derivative · entry 7 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,641 Underlying: Common Stock · 57,641 shares Expires 2027-02-28 F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document
February 28, 2017 Filed Mar 2, 2017 01:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantPerformance Share Units · Derivative	21,502	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005150 · doc4.xml · derivative · entry 6 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,502 Underlying: Common Stock · 21,502 shares Expires 2018-12-31 F6 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F7 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F7 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F7 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document
February 28, 2017 Filed Mar 2, 2017 01:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantDeferred Stock Units · Derivative	17,820	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005150 · doc4.xml · derivative · entry 5 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,820 Underlying: Common Stock · 17,820 shares Expires 2022-02-28 F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document
February 28, 2017 Filed Mar 2, 2017 01:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionDeferred Stock Units · Derivative	5,751	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005150 · doc4.xml · derivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,751 Underlying: Common Stock · 5,751 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document
February 28, 2017 Filed Mar 2, 2017 01:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	14,513	$24.55	$356,294.15	Disclosure SEC source: 0001225208-17-005150 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,630 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 28, 2017 Filed Mar 2, 2017 01:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	5,751	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005150 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 28, 2017 Filed Mar 2, 2017 01:54 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantCommon Stock	28,668	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005150 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,392 F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 28, 2017 Filed Jan 3, 2019 14:06 UTC Amendment	BOSTON SCIENTIFIC CORP BSX · Entity 1897	GrantPerformance Share Units · Derivative	21,502	$0.00	$0.00	Disclosure SEC source: 0001225208-19-000172 · doc4a.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,502 Underlying: Common Stock · 21,502 shares Expires 2018-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F2 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which is to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document
February 27, 2017 Filed Feb 28, 2017 21:45 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionDeferred Stock Units · Derivative	3,185	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004920 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,185 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document
February 27, 2017 Filed Feb 28, 2017 21:45 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	1,071	$24.81	$26,571.51	Disclosure SEC source: 0001225208-17-004920 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,724 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 27, 2017 Filed Feb 28, 2017 21:45 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	3,185	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004920 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 24, 2017 Filed Feb 27, 2017 21:27 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionDeferred Stock Units · Derivative	2,867	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004731 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 2,867 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document
February 24, 2017 Filed Feb 27, 2017 21:27 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	964	$24.78	$23,887.92	Disclosure SEC source: 0001225208-17-004731 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 24, 2017 Filed Feb 27, 2017 21:27 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	2,867	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004731 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 23, 2017 Filed Feb 24, 2017 21:18 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionDeferred Stock Units · Derivative	3,678	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004546 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,037 Underlying: Common Stock · 3,678 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document
February 23, 2017 Filed Feb 24, 2017 21:18 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	1,236	$24.48	$30,257.28	Disclosure SEC source: 0001225208-17-004546 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,707 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 23, 2017 Filed Feb 24, 2017 21:18 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	3,678	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004546 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 22, 2017 Filed Feb 23, 2017 22:00 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionDeferred Stock Units · Derivative	3,765	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004378 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,064 Underlying: Common Stock · 3,765 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document
February 22, 2017 Filed Feb 23, 2017 22:00 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	1,266	$25.16	$31,852.56	Disclosure SEC source: 0001225208-17-004378 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,265 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
February 22, 2017 Filed Feb 23, 2017 22:00 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	3,765	$0.00	$0.00	Disclosure SEC source: 0001225208-17-004378 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
January 01, 2017 Filed Jan 4, 2017 21:13 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionPerformance Share Units · Derivative	14,592	$0.00	$0.00	Disclosure SEC source: 0001225208-17-000350 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,592 shares Expires 2016-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.exercise_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.expiration_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. Read SEC document
January 01, 2017 Filed Jan 4, 2017 21:13 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Tax withholdingCommon Stock	5,185	$21.63	$112,151.55	Disclosure SEC source: 0001225208-17-000350 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,766 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document
January 01, 2017 Filed Jan 4, 2017 21:13 UTC	BOSTON SCIENTIFIC CORP BSX · Entity 1897	Exercise / conversionCommon Stock	14,592	$0.00	$0.00	Disclosure SEC source: 0001225208-17-000350 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.